Photo from wikipedia
Key Points Question Is there a difference in outcomes associated with sequential intravesical gemcitabine and docetaxel therapy vs bacillus Calmette-Guérin (BCG) therapy, the standard of care for the treatment of… Click to show full abstract
Key Points Question Is there a difference in outcomes associated with sequential intravesical gemcitabine and docetaxel therapy vs bacillus Calmette-Guérin (BCG) therapy, the standard of care for the treatment of high-risk non–muscle-invasive bladder cancer (NMIBC)? Findings In this cohort study of 312 patients with high-risk NMIBC, those receiving gemcitabine and docetaxel had better recurrence-free survival and a lower rate of induction treatment discontinuation than those receiving BCG. Meaning These findings suggest that gemcitabine and docetaxel may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage.
Journal Title: JAMA Network Open
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!